A PILOT STUDY ON IDENTIFICATION AND MANAGEMENT OF DRUG INDUCED SEXUAL DYSFUNCTION: A COLLABORATIVE APPROACH BY CLINICAL PHARMACIST AND PSYCHIATRIST
IDENTIFICATION AND MANAGEMENT OF DRUG INDUCED SEXUAL DYSFUNCTION
Objective: To assess the role of clinical pharmacists in the identification and management of drug-induced sexual dysfunction in collaboration with the psychiatrist and also to determine the prevalence and pattern of drug-induced sexual dysfunction, identify nature and extend of drug-induced sexual dysfunction, and assess the pattern of management of drug-induced sexual dysfunction.
Methods: This periodic prevalence interventional study was carried out among patients who visited the psychiatric department of a university hospital over three month’s period. Patients were screened for sexual dysfunction using the Arizona Sexual Experience Scale (ASEX) by study pharmacists.
Results: Of the 100 patients reviewed, only 50% of subjects met the study criteria. Depression (42%) was the most common clinical diagnosis among the study patients. The overall prevalence of drug-induced sexual dysfunction was 16%. A higher incidence of drug-induced sexual dysfunction was observed in men (62.5%). Decrease libido (40%) was the most prominently observed drug-induced sexual dysfunction in both genders. Antidepressant (50%) was the most common class of drugs implicated in sexual dysfunction. Drug-induced sexual dysfunction was pharmacologically managed with vaginal lubrication (40%), Tadalafil (20%) and Tadalafil+Dapoxetine combination (40%).
Conclusion: With this study, provided a vision, further how prospective studies in this arena may be carried out for better understanding drug-induced sexual dysfunction and how a clinical pharmacist can contribute for better health care of patients in the sex clinic by collaborating with medical practitioners.
2. Mkele G. A review of medicines that affect sexual performance. SA Pharm J 2014;81:34-7.
3. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-44.
4. Lucca JM, Ramesh M, Ram D, Kurian J, Mathew N. Psychotropic medication-induced sexual dysfunction and its interference with patient's daily performance: a cross-sectional study. Egyptian J Psychiatry 2016;37:36.
5. Conaglen HM, Conaglen JV. Drug-induced sexual dysfunction in men and women. Aust Prescr 2013;36:42.
6. Boora K, Chiappone K, Dubovsky SL. Oxcarbazepine-induced reversible anorgasmia and ejaculatory failure: a case report. Prim Care Companion J Clin Psychiatry 2009;11:173-4.
7. Calabro RS, Ferlazzo E, Italiano D, Bramanti P. Dose-dependent oxcarbazepine-related anorgasmia. Epilepsy Behav 2010; 17:287-8.
8. Calabro RS, Italiano D, Pollicino P, Bramanti P. Oxcarbazepine-related retrograde ejaculation. Epilepsy Behav 2012;25:174-5.
9. Martin Morales A, Ibanez J, Machuca M, Pol Yanguas E, Schnetzler G, Renedo VP. The EPIFARM study: an observational study in 574 community pharmacies in Spain characterizing patient profiles of men asking for erectile dysfunction medication. J Sex Med 2010;7:3153-60.
10. Mohandas E. Roadmap to Indian psychiatry. Indian J Psychiatry 2009;51:173.
11. Goldstein I, Krane RJ. Drug-induced sexual dysfunction. World J Urol 1983;1:239-43.
12. Gregorian Jr RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002;36:1577-89.
13. Lucca JM, Kurian J, Ramesh M, Ram D. Appraisal of clinical pharmacy services in the mental health unit of a South Indian tertiary care hospital. World J Pharm Pharm Sci 2014;3:780-91.
14. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden Watson C, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-66.
15. Serretti A, Chiesa A. Antidepressivi e disfunzione sessuale: epidemiologia, meccanismi e strategie di trattamento. Giornale Italiano Psicopatologia 2010;16:104-13.
16. La Torre A, Giupponi G, Duffy DM, Pompili M, Grozinger M, Kapfhammer HP, et al. Sexual dysfunction related to psychotropic drugs: a critical review–part I: antidepressants. Pharmacopsychiatry 2013;46:191-9.
17. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Human psychopharmacology. Hum Psychopharmacol 2008;23:201-9.
18. Macdonald S, Halliday J, MacEwan T, Sharkey V, Farrington S, Wall S, et al. Nithsdale schizophrenia surveys 24:sexual dysfunction: case-control study. Br J Psychiatry 2003;182:50-6.
19. Fan X, Henderson DC, Chiang E, Briggs LB, Freudenreich O, Evins AE, et al. Sexual functioning, psychopathology and quality of life in patients with schizophrenia. Schizophr Res 2007;94:119-27.
20. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982;170:463-7.
21. Fujii A, Yasui Furukori N, Sugawara N, Sato Y, Nakagami T, Saito M, et al. Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:288-93.
22. Knegtering H, Blijd C, Boks M. Sexual dysfunction and prolactin levels in patients using risperidone or olanzapine. Schizophr Res 2000;41:196.
23. La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grozinger M. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 2013;46:201-8.
24. Patnaik S, Polimati H, Pragada R. Erectile dysfunction and its pharmacology: an overview. Asian J Pharm Clin Res 2017;10:17-23.
25. Shekar D, Vazir M, Kempanna B, Miryala S, Subedi A. Effect of yohimbine on clomipramine-induced sexual dysfunction in male rats. Asian J Pharm Clin Res 2017;10:92.
26. Dossenbach M, Dyachkova Y, Pirildar S, Anders M, Khalil A, Araszkiewicz A, et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study. Eur Psychiatry 2006;21:251-8.
27. Calabro RS, Marino S, Bramanti P. Sexual and reproductive dysfunction associated with antiepileptic drug use in men with epilepsy. Expert Rev Neurother 2011;11:887-95.
This work is licensed under a Creative Commons Attribution 4.0 International License.